Vimarsana
Biggest News Aggregation in the World

Page 2 - Director Division News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Director Division. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Director Division Today - Breaking & Trending Today

"Center for circular economy in coffee" the first global collaborative platform for circular transition in coffee industry - Vimarsana News

"Center for circular economy in coffee" the first global collaborative platform for circular transition in coffee industry

Launch announced at the 5th World Coffee

European Union-Philippines Trade Conference highlights the need of going green for small businesses - Vimarsana News

European Union-Philippines Trade Conference highlights the need of going green for small businesses

(Manila/Geneva) As part of the EU-DTI Arise Plus Philippines project, the first European Union (EU)-Philippines Conference on green transition and trade was

European Union-Philippines Trade Conference Highlights The Need Of Going Green For Small Businesses - Vimarsana News

European Union-Philippines Trade Conference Highlights The Need Of Going Green For Small Businesses

Under the theme, ‘The Green Transition: Opportunities and Challenges for Philippine MSMEs’, the discussions at the conference highlighted the importance and

LUCIDITY phase 3 topline data presented at CTAD for HMTM - the only oral anti-Tau therapy in late-stage development - Vimarsana News

LUCIDITY phase 3 topline data presented at CTAD for HMTM - the only oral anti-Tau therapy in late-stage development

- Tau aggregation inhibitor, HMTM, is an oral drug with a strong safety profile, having no risk of amyloid related imaging abnormalities - Topline results for the Phase 3 study, LUCIDITY, were shared at the Clinical Trials in Alzheimer's Disease (CTAD) conference on Wednesday, 30th November 2022, in San Francisco - For people with early Alzheimer's (MCI), HMTM improvement in cognition over pre-treatment baseline now shown to be sustained over 18 months ABERDEEN, Scotland and SINGAPORE, Dec. 1, 2022 /PRNewswire/ --TauRx Pharmaceuticals Ltd is a global leader in Tau-based research in Alz...

TauRx Pharmaceuticals Ltd: LUCIDITY phase 3 topline data presented at CTAD for HMTM - the only oral anti-Tau therapy in late-stage development - Vimarsana News

TauRx Pharmaceuticals Ltd: LUCIDITY phase 3 topline data presented at CTAD for HMTM - the only oral anti-Tau therapy in late-stage development

- Tau aggregation inhibitor, HMTM, is an oral drug with a strong safety profile, having no risk of amyloid related imaging abnormalities - Topline results for the Phase 3 study, LUCIDITY